Haloperidol tablets - Approved for Marketing
On December 17, 2025, our company's fluphenazine tablets were approved for market release.
Haloperidol Injection - Approved for Marketing
On October 21, 2025, our company's haloperidol injection was approved for market release.
Lacosamide tablets - third-generation antiepileptic drugs
This product has been approved under the new registration category for chemical drugs, and is regarded as having passed the consistency assessment.
Okazepine tablets - Approved for Marketing
The national essential medicine and the medical insurance category A drug, Oxcarbazepine Tablets, has been approved for market release.
Gabapentin capsules - Approved for Marketing
The anti-epileptic drug - Gabapentin Capsules, which is classified as a category B drug in medical insurance, has been approved for market release.
Dapoxetine Hydrochloride Tablets - Approved for Marketing
The dapoxetine hydrochloride tablets have been approved under the new classification for chemical drugs.